Investors target Capricor Therapeutics in securities class action
A federal class action lawsuit alleges Capricor Therapeutics misled shareholders by altering clinical trial statistical protocols for its drug, Deramiocel, without prior FDA authorization. The litigation covers investors who purchased stock between December 17, 2025, and July 26, 2026, as the company faces claims of violating the Securities Exchange Act.





















